Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High?
AlloVir, Inc. (ALVR) closed the last trading session at $7.65, gaining 9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street ...
AlloVir, Inc. (ALVR) closed the last trading session at $7.83, gaining 45.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall ...
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has AlloVir, Inc. (ALVR) been one of those stocks this year? A ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AlloVir, Inc. (NASDAQ: ALVR) between March 22, 2022 and December 21, 2023, both ...
NEW YORK, NY / ACCESSWIRE / February 25, 2024 / If you suffered a loss on your AlloVir, Inc. (NASDAQ:ALVR) investment and want to learn about a potential recovery under the federal securities laws, ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...
As of February 8, 2023, the average one-year price target for Allovir is $26.78. The forecasts range from a low of $23.23 to a high of $31.50. The average price target represents an increase of 343.29 ...
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results